Peronální vinorelbin den 1. a den 8. v kombinaci s karboplatinou v léčbě nemocných s pokročilým nemalobuněčným karcinomem plic (NSCLC): výsledky nerandomizované studie u neselektované populace 396 nemocných

• Title in English: Oral vinorelbin Day 1 and 8 in combination with carboplatin in the treatment of patients withadvanced non-small cell lung cancer (NSCLC): Results of a non-randomized study of 396 non-selected patients
• Authors: SKŘIČKOVÁ Jana; KADLEC Bohdan; VENCLÍČEK Ondřej; JANÁSKOVÁ T.; BARTOŠ J.; CHALUPA J.; KOLEK V.; GRYGÁRKOVÁ I.; ČOUPKOVÁ H.; REITERER P.
• Year of publication: 2013
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: The evaluation of efficacy and safety of oral vinorelbin on day 1 and 8 in combination with carboplatin in the treatment of patients with advanced NSCLC was performed in 311 patients (78.5% men, 21.5% women, median age 65 years). A median of 4 cycles was administered. Vinorelbin was well tolerated, requiring a dose reduction in only 7.1% patients while escalation was possible in 19.5% patients. The dose of oral vinorelbin could remain unchanged in 67.7% patients.